Our platform technology is based on a simple, yet powerful principle: opposing angled microneedles that work in pairs to gently stretch the skin, allowing for full needle insertion to a prescribed depth, every time.
The Pharma Latch platform can be adapted into a range of device technologies providing an accurate/ repeatable intradermal delivery device solution for various use cases including pre-clinical testing in small animals to HCP-admin and self-injection devices for patients. No matter what the application is, all our devices use the same core technology. This platform approach allows us to customize devices to suit the needs of any stage of development or type of application, while maintaining consistency and precision.Whether you're conducting pre-clinical research, managing a clinical trial, administering an approved drug, or developing a drug requiring patient-friendly self-injector, Pharma Latch offers a proven, scalable solution that supports every stage of the R&D process and extends seamlessly into clinical and commercial use.
Our technology is designed to make intradermal delivery both easy and precise, unlocking the full potential of your therapy. Core benefits across our platform:
Easy-to-use devices with a simple clicking action, enabling anyone to deliver a perfect intradermal injection with confidence.
Ensures precise drug delivery with no leakage or spray back, allowing the entire dose to be fully delivered into the skin.
Supports up to 3 mL and 60 cP viscosity—capabilities traditionally not possible for intradermal delivery—eliminating the need for drug reformulation and opening the intradermal route for a broad range of applications, including mRNA drug delivery.
Device geometry (and not the user) governs injection depth, eliminating variability
Designed to support the entire R&D process—from pre-clinical testing in small animals to advanced self-injection devices.
No skin compression, low injection pressure, and shallow needles minimize discomfort for patients and reduce needle phobia.
Minimizing dead volume reduces injectate waste, making it particularly beneficial for high-value applications.
